Femasys receives second $500k FemBloc order from Kebomed for Europe

FEMASYS INC

Order valued at ~$500k for commercial launch of FemBloc in France and Benelux region.
Kebomed, a leading distributor, placed the order following Femasys' recent entry into Spain.
FemBloc is a non-surgical permanent contraceptive using a patented polymer to occlude fallopian tubes.
CEO Kathy Lee-Sepsick cited strategic partnerships driving international expansion and shareholder value.
No anesthesia, incisions, or recovery time required; addresses unmet need in reproductive health.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.